once signed by the president, our bill will: create a priority review timeline for qualified generic applications expedite the review and development of certain generics improve transparency and reporting requirements establish timelines for facility inspections this bill is a direct result of the investigation i led with susan collins in the senate aging committee, which has been the only bipartisan investigation into the causes, impacts, and potential solutions to the egregious price spikes consumers have seen in recent years. 